Peri‑implantitis and systemic inflammation: what the new reviews mean for your chairside practice

Peri‑implant inflammation may do more than destroy bone around an implant — evidence shows modest systemic inflammatory signals and underlines prevention, prompt treatment and medical collaboration, though causality is not proven.

Two recent reviews ask a timely question for everyday implant practice: does peri‑implantitis matter only locally, or can it influence a patient’s systemic inflammatory load? The Journal of Periodontal Research systematic review specifically examined the systemic footprint of peri‑implantitis, while a Periodontology 2000 review explored pathways linking oral dysbiosis (including peri‑implantitis) to broader systemic and even neuroinflammatory conditions. Both conclude that peri‑implant inflammation is biologically plausible as a contributor to low‑grade systemic inflammation, but the human evidence remains limited and heterogeneous. ([lifescience.net](

What the evidence actually shows is modest and mixed. Clinical studies and smaller interventional analyses report higher circulating inflammatory markers (for example, CRP and IL‑6) in patients with active peri‑implantitis compared with healthy implant controls, and at least one secondary analysis of a randomized trial found reductions in CRP and IL‑6 after non‑surgical peri‑implant treatment. These are small studies with varied definitions of disease and short follow‑up, so the effect sizes should be read as signals, not as proof of clinically important systemic disease. ([pmc.ncbi.nlm.nih.gov](

Why this matters in a busy private clinic: many implant patients have comorbidities (diabetes, cardiovascular risk, older age). If peri‑implantitis contributes even a small, persistent inflammatory burden, it may interact unfavourably with those conditions. That does not mean peri‑implantitis causes heart attacks or dementia on its own, but it strengthens the argument for prevention, timely treatment and sensible medical liaison in vulnerable patients. The Periodontology 2000 review highlights the stronger and more consistent evidence for periodontitis than for peri‑implantitis, and calls for better longitudinal and interventional studies specifically in implant populations. ([pubmed.ncbi.nlm.nih.gov](

Practical, evidence‑aligned steps you can use on Monday morning: (1) record systemic risks in the implant chart (diabetes control, cardiovascular history, immunosuppression) and explain that controlling local inflammation helps overall health; (2) prioritise prevention—good prosthetic emergence profiles, accessible contours for hygiene, regular maintenance recalls and early treatment of mucositis; (3) treat established peri‑implantitis promptly with staged, evidence‑based care (initial mechanical debridement and antisepsis, re‑evaluation and escalation to surgery when needed) and avoid reflexive prolonged antibiotic courses without clear indication. The current literature shows systemic marker reductions after local therapy, supporting that local control can lower systemic inflammation, even if long‑term clinical benefits outside the mouth remain unproven. ([pmc.ncbi.nlm.nih.gov](

A clinic‑level caution about regenerative aids: platelet‑rich fibrin and other autologous biologics are widely used for peri‑implant and periodontal regeneration, but persistent hyperglycemia impairs angiogenesis and the regenerative capacity of PRF. For patients with poorly controlled diabetes, do not rely on PRF alone to rescue compromised healing; focus first on improving glycemic control, communicate with the patient’s physician and set realistic expectations. ([eurekamag.com](

Limitations to keep in mind: definitions of peri‑implantitis vary between studies, sample sizes are often small, follow‑up short and confounders (smoking, residual periodontal pockets, prosthetic problems) are inconsistently reported. The current best interpretation is cautious: peri‑implantitis can be associated with modest systemic inflammatory changes, and treating the local disease reduces those markers in some studies — but we lack high‑quality long‑term data showing that this changes clinical outcomes such as cardiovascular events or cognitive decline. ([lifescience.net](

Bottom line for the implant clinic: treat peri‑implant health as part of general health. Prevent mucositis, detect and treat peri‑implantitis early, document systemic risks and liaise with medical colleagues for patients with uncontrolled systemic disease. These steps are low‑cost, fit routine clinic workflows and — supported by the recent reviews — are the right precautionary choice while stronger evidence accumulates.